Novel Agents in Gastroenteropancreatic Neuroendocrine Tumors

  • Ryan Stevenson Tufts University School of Medicine. Boston, MA, USA
  • Steven K Libutti Albert Einstein College of Medicine. Bronx, NY USA
  • Muhammad Wasif Saif Tufts University School of Medicine. Boston, MA, USA
Keywords: Carcinoid Tumor, Neuroendocrine Tumors, Octreotide, TOR Serine-Threonine Kinases, Therapeutics

Abstract

Neuroendocrine tumors (NET) are a diverse group of tumors that derive from epithelial cells with neuroendocrine differentiation. Gastroenteropancreatic neuroendocrine tumors are a subset of NET that arises in the gastrointestinal tract. Clinical symptoms and presentations vary depending on the location and hormones produced by the tumor. Treatment of advanced and metastatic gastroenteropancreatic NETs has traditionally been difficult with few systemic treatment options. In 2011, two new targeted therapies, everolimus and sunitinib were approved for treatment of pancreatic NET leading to increased interest in novel agents active in gastroenteropancreatic NETs. At the 2013 ASCO Gastrointestinal Cancers Symposium two abstracts presented new data regarding novel therapies. Lombard-Bohas et al. (Abstract #224) presented new data from the RADIANT-3 trial and Shen et al. (Abstract #322) looked at the use of octreotide in elderly patients with carcinoid syndrome.

Image: Tufts Medical Center Teddy Bear (Formerly F.A.O. Schwartz Teddy Bear). Boston, MA, USA.

Downloads

Download data is not yet available.

Author Biographies

Ryan Stevenson, Tufts University School of Medicine. Boston, MA, USA

Tufts Medical Center Fellow, Division of Hematology/Oncology

Steven K Libutti, Albert Einstein College of Medicine. Bronx, NY USA

Director, Montefiore-Einstein Center for Cancer Care Associate Director for Clinical Services, Albert Einstein Cancer Center
The Marvin L. Gliedman, M.D. Distinguished Surgeon
Professor and Vice-Chairman, Department of Surgery
Professor, Department of Genetics
Montefiore Medical Center/Albert Einstein College of Medicine

Muhammad Wasif Saif, Tufts University School of Medicine. Boston, MA, USA

Assistant Professor, Tufts University School of Medicine                                                          Director, Gastrointestinal Oncology Program                                                         Leader, Experimental Therapeutics Program

 

References

Yao, James C et al. "One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States." Journal of Clinical Oncology 26.18 (2008): 3063-3072. PMID: 18565894

Oberg, K. “Gastrointestinal Neuroendocrine Tumors.” Annals of Oncology Supplement 7.(2010):vii72-80.

Yao, James C et al. "Everolimus for advanced pancreatic neuroendocrine tumors." New England Journal of Medicine 364.6 (2011): 514-523. PMID: 21306238.

Raymond, Eric et al. "Sunitinib malate for the treatment of pancreatic neuroendocrine tumors." New England Journal of Medicine 364.6 (2011): 501-513. PMID: 21306237

Rinke, Anja et al. "Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group." Journal of Clinical Oncology 27.28 (2009): 4656-4663. PMID: 19704057

Lombard-Bohas et al. “Efficacy and safety of everolimus in patients with advanced low- or intermediate-grade pancreatic neuroendocrine tumors previously treated with chemotherapy: Radiant-3 subgroup analysis.” J Clin Oncol 2012; 30 (Suppl. 34): Abstract #224.

Shen et al. “Octreotide LAR use among elderly patients with carcinoid syndrome and survival outcomes: A population-based analysis.” J Cinical Oncology 2012; 30 (Suppl. 34): Abstract #322.

Pavel, Marianne E et al. "Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study." The Lancet 378.9808 (2011): 2005-2012. PMID: 22119496

Tufts Medical Center Teddy Bear (Formerly F.A.O. Schwartz Teddy Bear). Boston, MA, USA
Published
2013-03-10
How to Cite
StevensonR., LibuttiS., & SaifM. (2013). Novel Agents in Gastroenteropancreatic Neuroendocrine Tumors. JOP. Journal of the Pancreas, 14(2), 152-154. https://doi.org/10.6092/1590-8577/1470
Section
Highlights from the “2013 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 24-26, 2013

Most read articles by the same author(s)

1 2 > >>